Rapport Therapeutics, Inc. — financial figures as filed
RAPP · CIK 2012593 · 4 fiscal years on record
Aggregates
computed from the figures belowExplainable annual analytics
latest annual period where both published inputs exist| Metric | Value | Fiscal year | Inputs | Source tags |
|---|---|---|---|---|
| Return on assets | -21.8% | FY2025 | Net income: -$111.5MTotal assets: $512.4M | NetIncomeLoss / Assets |
| Return on equity | -23.0% | FY2025 | Net income: -$111.5MShareholders equity: $484.7M | NetIncomeLoss / StockholdersEquity |
| Liabilities / assets | 5.4% | FY2025 | Total liabilities: $27.8MTotal assets: $512.4M | Liabilities / Assets |
| Cash / assets | 10.3% | FY2025 | Cash and equivalents: $52.6MTotal assets: $512.4M | CashAndCashEquivalentsAtCarryingValue / Assets |
Not computed: Gross margin — both metrics are not available for a common annual period; Operating margin — both metrics are not available for a common annual period; Net margin — both metrics are not available for a common annual period; Operating cash-flow margin — both metrics are not available for a common annual period.
Mapping completeness
11 of 1211 of 12 canonical metrics were filled from this company's filings through the explicit tag map. Tags outside that map are recorded and counted, and are never used as a value.
Not on record for this company: Gross profit. This means the figure was not disclosed in a form we accept, not that it is zero.
Revenue by fiscal quarter
quarterly, as filed- 2025 Q1$0
- 2026 Q1$20M
Annual figures
4 fiscal years shown| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating income | -$125.1M | -$83.1M | -$36.2M | — |
| Net income | -$111.5M | -$78.3M | -$34.8M | — |
| Operating cash flow | -$87.5M | -$64.8M | -$27.2M | — |
| Total assets | $512.4M | $314.9M | $155.4M | — |
| Total liabilities | $27.8M | $9.5M | $14.5M | — |
| Shareholders equity | $484.7M | $305.4M | -$25.6M | -$10.1M |
| Cash and equivalents | $52.6M | $56.8M | $70.2M | — |
| Shares outstanding | 47,772,567 | 36,580,202 | 4,170,817 | — |
| EPS, basic | -$2.86 | -$3.78 | -$23.10 | — |
| EPS, diluted | -$2.86 | -$3.78 | -$23.10 | — |
Quarterly figures
10 fiscal quarters shown| Metric | 2026 Q1 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20M | — | — | $0 | — | — | — | — | — | — |
| Operating income | -$24.2M | -$30M | -$29.5M | -$27.1M | -$21.6M | -$20.8M | -$17.1M | -$9.6M | -$6.6M | — |
| Net income | -$19.9M | -$26.9M | -$26.7M | -$24.1M | -$17.5M | -$18.1M | -$22.7M | -$8.7M | -$6.4M | -$6.1M |
| Operating cash flow | -$13.1M | — | — | -$20.2M | — | — | -$17.6M | — | — | — |
| Total assets | $497.6M | $535.3M | $285.5M | $302.1M | $331.1M | $346.1M | — | — | — | — |
| Total liabilities | $26.1M | $23.7M | $22M | $16.2M | $8M | $9.2M | — | — | — | — |
| Shareholders equity | $471.5M | $511.6M | $263.5M | $285.8M | $323.1M | $336.9M | -$39.6M | -$13.1M | -$9.4M | -$4M |
| Cash and equivalents | $78.1M | $251.4M | $55.1M | $57.6M | $39.3M | $110.2M | $74.3M | $159.4M | $79.5M | — |
| Shares outstanding | 47,807,453 | 47,650,216 | 36,497,677 | 36,497,434 | 36,576,457 | 36,576,457 | — | — | — | — |
| EPS, basic | -$0.42 | -$0.71 | -$0.75 | -$0.68 | -$0.50 | -$1.70 | -$11.07 | -$5.70 | -$4.45 | — |
| EPS, diluted | -$0.42 | -$0.71 | -$0.75 | -$0.68 | -$0.50 | -$1.70 | -$11.07 | -$5.70 | -$4.45 | — |
Latest figure against the peer median
all 722 companies with figures on record| Metric | Latest annual figure | Peer median | Difference | Companies in group | Source tag |
|---|---|---|---|---|---|
| Operating income · FY2025 | -$125.1M | -$3.8M | −3,196.4% | 591 | OperatingIncomeLoss |
| Net income · FY2025 | -$111.5M | $2.4M | −4,656.1% | 716 | NetIncomeLoss |
| Operating cash flow · FY2025 | -$87.5M | $20.1M | −534.9% | 715 | NetCashProvidedByUsedInOperatingActivities |
| Total assets · FY2025 | $512.4M | $1.1B | −54.1% | 720 | Assets |
| Total liabilities · FY2025 | $27.8M | $458.2M | −93.9% | 664 | Liabilities |
| Shareholders equity · FY2025 | $484.7M | $301M | +61.0% | 716 | StockholdersEquity |
| Cash and equivalents · FY2025 | $52.6M | $82.6M | −36.3% | 688 | CashAndCashEquivalentsAtCarryingValue |
| Shares outstanding · FY2025 | 47,772,567 | 49,628,137 | −3.7% | 606 | CommonStockSharesOutstanding |
| EPS, basic · FY2025 | -$2.86 | $0.05 | −5,820.0% | 678 | EarningsPerShareBasic |
| EPS, diluted · FY2025 | -$2.86 | $0.03 | −11,540.0% | 678 | EarningsPerShareDiluted |
Where the numbers come from
every figure traces to a filing| Metric | Fiscal period | Period end | Filed | Form | Accession | XBRL tag |
|---|---|---|---|---|---|---|
| Operating income | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | OperatingIncomeLoss |
| Net income | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | NetIncomeLoss |
| Operating cash flow | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | NetCashProvidedByUsedInOperatingActivities |
| Total assets | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | Assets |
| Total liabilities | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | Liabilities |
| Shareholders equity | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | StockholdersEquity |
| Cash and equivalents | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | CashAndCashEquivalentsAtCarryingValue |
| Shares outstanding | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | CommonStockSharesOutstanding |
| EPS, basic | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | EarningsPerShareBasic |
| EPS, diluted | FY2025 | 2025-12-31 | 2026-03-10 | 10-K | 0001193125-26-099360 | EarningsPerShareDiluted |
Source: U.S. Securities and Exchange Commission, EDGAR company facts · as of 2026-03-10